menu

Reducing Cardiovascular Risk with PCSK9 Inhibitors: Addressing Challenges and Improving Outcomes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing Cardiovascular Risk with PCSK9 Inhibitors: Addressing Challenges and Improving Outcomes

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
  • Overview

    Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.

  • Disclosure of Conflicts of Interest

    Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

  • Target Audience

    Healthcare professionals who manage patients with cardiovascular disease

  • Learning Objectives

    • Discuss current nonstatin LDL-C-lowering therapies and guideline recommendations for treating high LDL-C
    • Describe clinical outcome trial evidence with ezetimibe and PCSK9 inhibitors
    • Identify very high risk patients with atherosclerotic cardiovascular disease (ASCVD) in whom PCSK9 inhibitors have demonstrated cardiovascular risk reduction
    • Explain the need to lower LDL-C early and intensively if patients are not at LDL-C goals after an acute coronary syndrome (ACS), and the data with PCSK9 inhibitors in post-ACS patients
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.

  • Disclosure of Conflicts of Interest

    Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

  • Target Audience

    Healthcare professionals who manage patients with cardiovascular disease

  • Learning Objectives

    • Discuss current nonstatin LDL-C-lowering therapies and guideline recommendations for treating high LDL-C
    • Describe clinical outcome trial evidence with ezetimibe and PCSK9 inhibitors
    • Identify very high risk patients with atherosclerotic cardiovascular disease (ASCVD) in whom PCSK9 inhibitors have demonstrated cardiovascular risk reduction
    • Explain the need to lower LDL-C early and intensively if patients are not at LDL-C goals after an acute coronary syndrome (ACS), and the data with PCSK9 inhibitors in post-ACS patients
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule27 Jun 2022
Webpack App